Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | JAX:10000006 |
Name | Cancer of Unknown Primary |
Definition | Cancer for which the tissue of origin cannot be determined |
Source | Genomenon (a custom term added that does not correspond to an existing term in the disease ontology) |
Alt Ids | |
Path | Cancer of Unknown Primary |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MLH1 negative | Pembrolizumab | Cancer of Unknown Primary | sensitive | detail... |
MSH6 negative | Pembrolizumab | Cancer of Unknown Primary | sensitive | detail... |
ALK rearrange | Crizotinib | Cancer of Unknown Primary | sensitive | detail... |
ALK rearrange | Alectinib | Cancer of Unknown Primary | sensitive | detail... |
ALK rearrange | Ceritinib | Cancer of Unknown Primary | sensitive | detail... |
ALK rearrange | Brigatinib | Cancer of Unknown Primary | sensitive | detail... |
ROS1 rearrange | Crizotinib | Cancer of Unknown Primary | sensitive | detail... |
FGFR2 amp | Infigratinib + Trametinib | Cancer of Unknown Primary | sensitive | detail... |
FGFR2 S267P | Erdafitinib | Cancer of Unknown Primary | predicted - sensitive | detail... |
BRAF V600E | Binimetinib + Cetuximab | Cancer of Unknown Primary | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03752333 | Phase II | Pembrolizumab | Trial of Pembrolizumab in Cancer of Unknown Primary (CUPem) | Active, not recruiting | GBR | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |